GSK

Latest news

• NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? (opens in a new tab)

  Stocktwits · Oct 1, 2026

• GSK (GSK) reports 4.05B voting rights, with 271M shares held in treasury (opens in a new tab)

  Stock Titan · Oct 1, 2026

• GSK adds liver candidate from Wave RNA partnership (opens in a new tab)

  European Biotechnology Magazine · Oct 1, 2026

• Tyler Reynolds Joins GSK as Director, Digital Medicine (opens in a new tab)

  BioBuzz · Oct 1, 2026

• GSK Stockmann advises Target Global on Health Force investment (opens in a new tab)

  ICLG · Oct 1, 2026

• GSK slides Wednesday, underperforms market (opens in a new tab)

  MarketWatch · Sep 30, 2026

• GSK Taps Wave Life Sciences’ siRNA Program, Triggering $12M Milestone Payment (opens in a new tab)

  Genome Web · Sep 30, 2026

• GSK continues to stock up on Wave's RNA drugs with liver-focused program (opens in a new tab)

  Fierce Biotech · Sep 30, 2026

• Wave to receive $12M milestone from GSK (WVE:NASDAQ) (opens in a new tab)

  Seeking Alpha · Sep 30, 2026

• Wave Life Sciences Announces GSK Advances Hepatology Candidate from SpiNA siRNA Collaboration (opens in a new tab)

  Quiver Quantitative · Sep 30, 2026

• Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development (opens in a new tab)

  globenewswire.com · Sep 30, 2026

• GSK selected a liver candidate for development, triggering $12 million for Wave. (opens in a new tab)

  Stock Titan · Sep 30, 2026

• GSK (LSE:GSK) The Latest Update Raises A Bigger Question (opens in a new tab)

  Yahoo Finance · Sep 30, 2026

• 5 minutes with Tia Vincent, GSK (opens in a new tab)

  European Medical Journal · Sep 29, 2026

• Spotlight On: GSK's HBV hopeful tops FDA's October agenda (opens in a new tab)

  firstwordpharma.com · Sep 29, 2026

• GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated (opens in a new tab)

  Proactive financial news · Sep 29, 2026

• Gates Foundation Extends Funding for AN2 Therapeutics, GSK Research Collab (opens in a new tab)

  Contract Pharma · Sep 28, 2026

• AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK (opens in a new tab)

  Business Wire · Sep 28, 2026

• GSK PLC | British Pharmaceutical & Biotechnology Company (opens in a new tab)

  Britannica · Sep 26, 2026

• Emma Walmsley | Former GSK CEO & British Business Executive (opens in a new tab)

  Britannica · Sep 26, 2026

• GSK reprimanded for lack of transparency in vaccine campaign case (opens in a new tab)

  medwatch.com · Sep 25, 2026

• How splitting from GSK taught Haleon a spin-off is not a finish line (opens in a new tab)

  Semafor · Sep 25, 2026

• GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger? (opens in a new tab)

  Yahoo Finance · Sep 24, 2026

• GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity (opens in a new tab)

  Yahoo Finance · Sep 24, 2026

• GSK slammed for ‘grossly misleading’ and ‘totally unacceptable’ behavior (opens in a new tab)

  Fierce Pharma · Sep 24, 2026

• At a listed price of $50.72, GSK (NYSE: GSK) president acquires 9.414 notional shares in her savings plan (opens in a new tab)

  Stock Titan · Sep 24, 2026

• GSK's Jemperli (dostarlimab) accepted for review by Health Canada for patients with dMMR/MSI-H locally advanced rectal cancer (opens in a new tab)

  BioSpace · Sep 24, 2026

• Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum (opens in a new tab)

  Yahoo Finance · Sep 24, 2026

• $3.3 Million in New Philanthropic Commitments for Good Jobs Western North Carolina From The Rockefeller Foundation, John M. Belk Endowment, and NC GSK Foundation (opens in a new tab)

  The Rockefeller Foundation · Sep 24, 2026

• GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care (opens in a new tab)

  es.tradingview.com · Sep 23, 2026